Dr. Toby Trujillo discusses the COLCOT trial.
Episode Breakdown:
0:00-0:40: Intro
0:41-1:30: Introduction of Dr. Toby Trujillo
1:31-3:56: COLCOT overview
3:57-4:50: Toby’s initial thoughts
4:51-6:08: Anti-inflammatory agents
6:09-7:09: Pneumonia?
7:10-8:29: Baseline Management of Patients
8:30-10:15: Who is the niche colchicine patient?
10:16-12:05: Drug burden and cost
12:06-13:03: Follow-up period
13:04-13:59: Final thoughts
14:00-14:44: Closing
References:
- COLCOT Trial: Tardif J, Kouz S, Water DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019;381:2497-505.
- CANTOS Trial: Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.
- CIRT Trial: Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752-62.
- LoDoCo Trial: Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-10.
CardioScripts 